Genmab Files Annual Report with the U.S. Securities and Exchange Commission
(WorldNews Denmark)

Supporting Materials: 300320_i05_20F Filing PDF Version Media Release Copenhagen, Denmark, March 30, 2020 Genmab filed Form 20-F for the financial year 2019 with the U.S. SEC Genmab A/S (Nasdaq: GMAB) announced today that it has filed its Annual Report for the financial year 2019 on Form 20-F with the U.S. Securities and Exchange Commission (SEC), incorporating by reference parts of the Genmab A/S Annual Report 2019. Both reports are available via the SEC`s website, www.sec.gov and Genmab`s website, www.genmab.com. About Genmab Genmab is a publicly traded, international biotechnology company specializing in the creation and development of differentiated antibody therapeutics for the...